Oral contraceptives and menopausal hormone therapy as breast cancer risk categories
https://doi.org/10.17650/1994-4098-2019-15-2-42-51
Abstract
The research provided includes analysis of the current state of the problem on the use of oral contraceptives and menopausal hormone therapy. These therapeutic options were evaluated in terms of their importance for the risk of breast cancer. The possibility of using these drugs in a cohort of high-risk patients (women with family history of breast cancer) and in the group of patients with benign pathology was analyzed as well. Modern trends of menopausal hormone therapy prescription in different clinical situations were determined.
About the Authors
I. V. Vуsotskaya
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation
8/2 Trubetskaya St., Моscow 119991
Russian Federation
8/2 Trubetskaya St., Моscow 119991
V. P. Letyagin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
I. K. Vorotnikov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
V. U. Kirsanov
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation
8/2 Trubetskaya St., Моscow 119991
Russian Federation
8/2 Trubetskaya St., Моscow 119991
I. A. Gladilina
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
E. A. Kim
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
References
1. Vessey M., Yeates D. Oral contraceptives and bening breast disease: an update of finding in a large cohort study. Contraception 2007;76(6):418–24. DOI: 10.1016/j.contraception.2007.08.011.
2. Cibula D., Gompel A., Mueck A.O. et al. Hormonal contraception and risk of cancer. Hum Reprod Upd 2010;6(16):631–50. DOI: 10.1093/humupd/dmq022.
3. Savel’eva I.S. The effect of hormonal contraceptives on the risk of developing breast cancer. Ginekologiya = Gynecology 1999;1(1). (In Russ.)
4. Ul’rikh E.A., Kutusheva G.F., Urmancheeva A.F. Oncological aspects of contraception. Prakticheskaya onkologiya = Practical Oncology 2009;10(4):254–64. (In Russ.)
5. Prokop’eva T.A., Gorbunova E.E. Hormone replacement therapy and breast cancer. Prakticheskaya meditsina = Practical Medicine 2011;6(54):23–8. (In Russ.)
6. Payanidi U.G., Kazubskaya T.P., Sel’chuk V.U. et al. Hormonal contraception and cancer. Pros and cons. Onkoginekologiya = Oncogynecology 2012;(3):10–6. (In Russ.)
7. Roberts D.L., Dive C., Renehan A.G. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med 2010;61:301–16. DOI: 10.1146/annurev.med.080708.082713.
8. Hannaford P.C., Iversen L., Macfarlane T.V. et al. Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners’ Oral Contraception Study. BMJ 2010;340:c927. DOI: 10.1136/bmj.c927.
9. Department of Reproductive Health, World Health Organization. Medical eligibility criteria for contraceptive use. 4 th edn., 2010. 121 p.
10. Visotskaya I.V., Letyagin V.P. Benign breast diseases. Moscow: MIA, 2019. 107 p. (In Russ.)
11. World Health Organization. Medical eligibility criteria for contraceptive use. 5th edn., 2017. 192 p. (In Russ.)
12. Marchbanks P.A., McDonald J.A., Wilson H.G. et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002;346(26):2025–32. DOI: 10.1056/NEJMoa013202.
13. Zhu H., Lei X., Feng J., Wang Y. Oral contraceptive use and risk of breast cancer: a meta-analysis of prospective cohort studies. Eur J Contracept Reprod Health Care 2012;17(6):402–14. DOI: 10.3109/13625187.2012.715357.
14. Podzolkova N.M. Hormonal contraception, safety and portability issues. Mat’ i ditya. Russkiy meditsinskiy zhurnal = Mother and child. Russian Medical Journal 2009;(1):5–11. (In Russ.)
15. Silvera S.A.N., Miller A.B., Rohan T.E. Oral contraceptive use and risk of breast cancer among women with a family history of breast cancer: a prospective cohort study. Cancer Causes Control 2005;16:1059–63.
16. Brunner L.R., Hogue C.J. The role of body weight in oral contraceptive fail- ure: results from the 1995 national survey of family growth. Ann Epidemiol 2005;15(7):492–9. DOI: 10.1016/j.annepidem.2004.10.009.
17. Gronwald J., Byrski T., Huzarski T. et al. Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. Breast Cancer Res Treat 2006;95:105–9. DOI: 10.1007/s10549-005-9051-5.
18. Haile R.W., Thomas D.C., McGuire V. et al. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol Biomarkers Prev 2006;15(10):1863–70. DOI: 10.1158/1055-9965.EPI-06-0258.
19. Gaffield M.E., Culwell K.R., Ravi A. Oral contraceptives and family history of breast cancer. Contraception 2009;80(4):372–80. DOI: 10.1016/j.contraception.2009.04.010.
20. Iodice S., Barile M., Rotmensz N. et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer 2010;46:2275– 84. DOI: 10.1016/j.ejca.2010.04.018.
21. Milne R.L., Knight J.A., John E.M. et al. Oral contraceptive use and risk of earlyonset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 2005;14(2):350–6. DOI: 10.1158/1055-9965.EPI-04-0376.
22. Narod S., Dube M.P., Klijn J. et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2002;94(23):1773–9.
23. Polonsky M. Cancer and contraception. Release date: May 2012, SFP Guideline. Contraception 2012;86(3):191–8. DOI: 10.1016/j.contraception.2012.05.008.
24. Mody S.K., Panelli D.M., Hulugalle A. et al. Contraception concerus, utilization and conseling needs of women with a history of breast cancer, a qualitative study. Int J Women Health 2017;9:507–12. DOI: 10.2147/IJWH.S136120.
25. Menopausal hormone therapy and preservation of the health of women of mature age. Clinical guidelines: protocols. Project (Moscow, 2015). Klimakteriy = Klimaktery 2014;(4):8–31. (In Russ.).
26. Lund E., Bakken K., Dumeaux V. et al. Hormone replacement therapy and breast cancer in former users of oral сontraceptives – The Norwegian women andcancer study. Int J Cancer 2007;121:645–8. DOI: 10.1002/ijc.22699.
27. Пресс-релиз Международной ассоциации по менопаузе от 5 июля 2012 г.
28. Lyytinen H., Pukkala E., Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol 2009;113(1): 65–73. DOI: 10.1097/AOG.0b013e31818e8cd6.
29. Fournier A., Berrino F., Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107(1):103–11. DOI: 10.1007/s10549-007-9523-x.
30. Fournier A., Fabre A., Mesrine S. et al. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol 2008;26(8):1260–8. DOI: 10.1200/JCO.2007.13.4338.
31. De Villiers T.J., Gass M.L.S., Haines C.J. et al. Global consensus statement on menopausal hormone therapy. Climacteric 2013;16(2):203–4. DOI: 10.3109/13697137.2013.771520.
32. Baber R.J., Panay N., Fenton A., IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016;19(2):109–50. DOI: 10.3109/13697137.2015.1129166.
33. Kotsopoulos J., Huzarski T., Gronwald J. et al. Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers. JAMA Oncol 2018;4(8):1059–65. DOI: 10.1001/jamaoncol.2018.0211.
34. Finch A., Metcalfe K.A., Chiang J. et al. The impact of prophylactic salpingooophorectomy on quality of life and psychological distress in women with a BRCA mutation. Psychooncology 2013;22(1):212–9. DOI: 10.1002/pon.2041.
35. Lippman S.M., Hawk E.T. Cancer prevention: from 1727 to Milestones of the past 100 years. Cancer Res 2009;69(13):5269– 84. DOI: 10.1158/0008-5472.CAN-09-1750.
36. Parker W.H., Shoupe D., Broder M.S. et al. Effective oophorectomy in the gynecological patient: when is it desirable? Curr Opin Obstet Gynecol 2007;19(4):350–4. DOI: 10.1097/GCO.0b013e32821642d1.
37. Gabriel C.A., Tigges-Cardwell J., Stopfer J. et al. Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oopho- rectomy. Familial Cancer 2009;8:23–8. DOI: 10.1007/s10689-008-9208-6.
38. Protasova A.E., Yureneva S.V., Vandeeva E.N. Menopausal hormone therapy and risk factors of breast cancer development. Ginekologiya = Gynecology 2017;19(3):23–9. (In Russ.). DOI: 10.26442/2079-5696_19.3.23-29.
39. Wuttke W., Jarry H., Westohaeen S. et al. Are the phytoestrogens an alternative of replacement hormone therapy? Gynecology 2002;9–20.
40. Wuttke W., Seidlova-Wuttke D., Grkow C. The Cimicifuga preparation BNO 1055 vs conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers. Maturitas 2003;44(suppl 1):67–77. DOI: 10.1016/S0378-5122(02)00350-X.
41. Hernández Muñoz G., Pluchino S. Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer. Maturitas 2003;44(suppl 1): S59–65.
Review
For citations:
Vуsotskaya I.V., Letyagin V.P., Vorotnikov I.K., Kirsanov V.U., Gladilina I.A., Kim E.A. Oral contraceptives and menopausal hormone therapy as breast cancer risk categories. Tumors of female reproductive system. 2019;15(2):42-51. (In Russ.) https://doi.org/10.17650/1994-4098-2019-15-2-42-51
Views:
731
Email this article 